Friday, November 13, 2026
ExploreSearch
Via News

Forex Trading

2 articles

Dollar Index Crashes 10.8% as Forex Markets Enter Volatility Phase

Dollar Index Crashes 10.8% as Forex Markets Enter Volatility Phase

The US Dollar Index dropped 10.8% in early 2026 to its lowest point since 2022, triggering widespread currency realignment. GBP/USD faces pressure toward $1.30 despite 7% gains in 2025, while safe-haven flows boost the Swiss Franc amid systemic instability concerns.

ViaNews Editorial Team (Markets)•
GBP/USD Slides to $1.3086 as Dollar Index Plunges 10.8%, Swiss Franc Draws Safe-Haven Flows

GBP/USD Slides to $1.3086 as Dollar Index Plunges 10.8%, Swiss Franc Draws Safe-Haven Flows

The US Dollar Index has tumbled 10.8% in early 2026 to its lowest level since 2022, triggering currency market volatility across major pairs. GBP/EUR dropped to €1.13, the weakest since April 2023, while analysts forecast Sterling could breach $1.30. Safe-haven demand pushed flows into the Swiss Franc as traders position ahead of the Fed leadership transition in June 2026.

ViaNews Editorial Team (Markets)•
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Late-2026 Biotech Catalyst Season: FDA Decisions and Pivotal Readouts Converge Across Oncology, Hepatology and Cardiometabolic
Mid-November 2026 is dense with scheduled biotech catalysts. The ivonescimab BLA PDUFA date is 2026-11-14, the lorundrostat PDUFA date is 2026-12-22, and Phase 3 ECLIPSE hepatitis delta data are due in Q1 2027. Alongside these, siRNA and antibody programs (plozasiran, elebsiran/tobevibart, ianalumab, nipocalimab) reported or presented data at AHA, AASLD, ACR and ASH, while Oryzon advanced iadademstat in AML with Spanish trial authorizations and a planned ALICE-3 Phase III. Late-stage data and regulatory milestones are driving the sentiment. A planned delisting (EGM 2026-11-19, application 2027-01-25) is a separate corporate-structure event with no clear link to the rest.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,577 source documents archived
Query this data → isubstrate.com